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(57) ABSTRACT 
Polynucleotides that comprise regulatory regions of the 
yeast alcohol oxidase 1 promoter are provided. Isolated 
polynucleotides, recombinant polynucleotides, vectors, 
expression cassettes and transformed cells containing the 
regulatory regions are disclosed. Proteins produced by the 
transformed cells are also provided. 
20 Claims, 6 Drawing Sheets 


U.S. Patent Mar. 2, 2004 Sheet 3 6f 6 US 6,699,691 B2 
FIGURE 3 
U.S. Patent Mar. 2, 2004 Sheet 4 6f 6 US 6,699,691 B2 
MM grown cell extract MME grown cell extract 
Probe 7 Y Y a 
1 2 3 4 5 6 7 8 9 
FIGURE 4 
U.S. Patent Mar. 2, 2004 Sheet 5 6f 6 US 6,699,691 B2 
FIGURE 5 
U.S. Patent Mar. 2, 2004 Sheet 6 6f 6 US 6,699,691 B2 
A 
Pos +/— Sequence Fragment 
—726 + gctcaTTCCAAttcct A Seq. ID No. 6 
—519 - ctgtcTTGGAAcctaa C Seq. ID No. 7 
—428 + gaaacTTCCAAaagtc C Seq. ID No. 8 
—245 + tatgcTTCCAAgattc E Seq. ID No. 9 
—79 + actggTTCCAAttgac F Seq. ID No. 10 
B 
—677 - cctgtCTATCctggc _ B Seq. ID No. 11 
—340 — tctctCTATCgcttc D Seq. ID No. 12 
—218 + ctgctGATAGcctaa E Seq. ID No. 13 
C 
Moxuas2 T OGTG Seq ID No 14 
Aoxlp -583 G GGT ‘ ‘ ‘ c Seq: ID No: 15 
Consensus gagt g ggtc 
FIGURE 6 
US 6,699,691 B2 
1 
ALCOHOL OXIDASE 1 REGULATORY 
NUCLEOTIDE SEQUENCES FOR 
HETEROLOGOUS GENE EXPRESSION IN 
YEAST 
FIELD OF THE INVENTION 
The current invention is generally directed toward iso 
lated polynucleotides comprising regulatory nucleotide 
sequences, vectors and expression cassettes containing such 
regulatory sequences, and host cells comprising the vectors 
and/or expression cassettes. In particular, the invention 
relates to 5‘ upstream regulatory nucleotide sequences 
Within the promoter region of the alcohol oxidase 1 gene, 
vectors and expression cassettes containing such regulatory 
sequences, and host cells comprising the vectors and/or 
expression cassettes. 
BACKGROUND OF THE INVENTION 
Methylotrophic yeast are capable of utiliZing methanol as 
their sole energy source. The methylotrophic yeast comprise 
tWo groups, the asporagenous consisting of the Candida and 
Torulopsis species, and the ascomycetous consisting of the 
Hansenula and Pichia species. These yeast possess a con 
served methanol utiliZation pathWay. In the ?rst step of this 
pathWay, the enZyme alcohol oxidase catalyZes the oxidation 
of methanol to formaldehyde. Concomitantly, this reaction 
also generates hydrogen peroxide, a substance that is highly 
toxic to most cellular organelles. In order to avoid hydrogen 
peroxide toxicity, methanol metabolism is highly compart 
mentaliZed in specialiZed organelles, called peroxisomes, 
Which sequester this toxic byproduct from the rest of the 
cell. Alcohol oxidase has a loW af?nity for its substrate, 
oxygen. The partitioning of alcohol oxidase in the 
peroxisome, therefore, serves the additional role of concen 
trating the enZyme and substrate, thereby compensating, at 
least in part, for its loW oxygen affinity. 
The regulation of methanol metabolism in yeast generally 
occurs at the level of transcription, and includes control of 
the synthesis and activation of corresponding enZymes, as 
Well as their degradation. Synthesis of methanol metaboliZ 
ing enZymes is induced by methanol, formaldehyde and 
formate, and repressed by both glucose and ethanol. As 
stated above, a key enZyme in methanol oxidation is alcohol 
oxidase, Which is also controlled both positively and nega 
tively at the transcription level. Several genes encoding 
alcohol oxidase from Pichia pastoris (AOX1 and AOX2), 
Candida boidinii S2 (AOD1), and methanol oxidase from 
Hansenula polymorpha (MOX1) are Well characteriZed. 
Methanol induction causes the rapid de novo synthesis of 
alcohol oxidase, Which is accompanied by a corresponding 
increase in alcohol oxidase mRNA. For example, in metha 
nol groWn R pastoris cells, AOX rapidly accumulates up to 
30% of the total soluble protein. 
Yeasts have been extensively employed for the production 
of heterologous proteins and offer several advantages over 
prokaryotic expression systems. For example, some eukary 
otic proteins that are produced in prokaryotic cells are either 
unstable or lack biological activity. Accordingly, in these 
cases, yeasts offer advantages over their prokaryotic coun 
terparts Which include an intracellular environment that is 
more conducive for correct folding of eukaryotic proteins. 
Additionally yeasts, unlike prokaryotic hosts, have the abil 
ity to glycosylate proteins, Which is important for both the 
stability and biological activity of the protein. 
Saccharomyces cerevisiae Was the ?rst, and remains the 
most commonly employed eukaryotic expression system 
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because its genome and physiology have been extensively 
characteriZed. It is not alWays the optimal expression 
system, hoWever, for the large-scale production of heterolo 
gous proteins because of plasmid loss during scale-up, 
hyperglycosylation, and loW protein yields. Recently, 
methylotrophic yeast expression systems have been devel 
oped and offer several advantages over their counterpart, S. 
cerevisiae. For example, methylotrophic yeast expression 
systems achieve very high cell densities in a simple de?ned 
medium, have strong inducible promoters, and the availabil 
ity of methods, host strains, and expression vectors that 
facilitate genetic manipulations. 
In particular, the methylotrophic yeast, R pastoris, has 
been extensively utiliZed for the production of heterologous 
proteins at the industrial scale. R pastoris is a particularly 
suitable expression system for the production of proteins at 
the industrial scale because of the presence of a unique 
promoter, AOX1, used to drive gene expression. The AOX1 
promoter, as stated above, is derived from the methanol 
regulated alcohol oxidase I gene and is one of the most 
efficient and tightly regulated promoters knoWn. For 
example, as delineated above, in methanol groWn R pastoris 
cells, AOX rapidly accumulates up to 30% of the total 
soluble protein. 
In addition to the AOX1 gene, R pastoris also harbors a 
second functional AOX gene, AOX2. AOX2 encodes a 
protein that shares approximately 97% homology, and has 
the same speci?c activity as its AOX1 counterpart. HoWever, 
the 5‘ upstream regulatory regions of AOX1 and AOX2 do 
not have signi?cant regions of homology, despite the fact 
that both genes are repressed during groWth on glucose, 
derepressed during carbon limitation, and induced by 
groWth on methanol as the sole carbon source. In addition, 
AOX2 induction is responsible for only 15% of total alcohol 
oxidase activity in methanol-groWn cell cultures. Due to the 
limited accumulation of AOX2 relative to AOX1, the AOX1 
promoter is more advantageous to employ in an expression 
system for large-scale protein production. 
Although high-level expression of heterologous proteins 
has been achieved employing the AOX1 promoter from R 
pastoris, very little is knoWn about the molecular mecha 
nisms involved in methanol induction, either in R pastoris 
or methylotrophic yeasts in general. The promoter region for 
AOX1 has been identi?ed (SEQ ID NO: 1), hoWever, 
regulatory sequences Within this region have not been exten 
sively characteriZed. See Stroman et al., US. Pat. No. 
4,855,231. In addition, the promoter region for the AOX2 
gene has also been identi?ed (SEQ ID NO: 2), and consists 
of three cis-acting regulatory elements that have been char 
acteriZed (one positive and the other tWo negative). See 
Cregg., US. Pat. No. 5,032,516. The positive cis-acting 
element, the AOX2 upstream activator site, is required for a 
response to transcriptional induction by methanol. The tWo 
negative cis-acting elements are responsible for repression 
of the AOX2 promoter. HoWever, as delineated above, the 5‘ 
upstream regulatory regions of AOX1 and AOX2 do not 
have signi?cant regions of homology and thus, the extensive 
characteriZation of AOX2 regulation provides little insight 
into the mechanism by Which the AOX1 promoter is regu 
lated. 
In yet a further attempt to characteriZe regulatory regions 
of the AOX1 promoter, its sequence Was compared to the 5‘ 
upstream regulatory regions of an alcohol oxidase gene, 
ZZA (SEQ ID NO: 3), isolated from an uncharacteriZed R 
pastoris strain. See Kumagai et al., US. Pat. No. 5,641, 661. 
This strain also contains tWo copies of the AOX genes. The 
deduced amino acid sequence of ZZA revealed that 14 of the 
US 6,699,691 B2 
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?rst 16 amino acids are identical to that of the AOX1 and 
AOX2 genes. However, similar to the 5‘ regulatory regions 
of AOX1 and AOXZ, the 5‘ upstream regulatory regions of 
ZZA and AOX1 share only 66% homology. The tWo 
promoters, thus, may be regulated by completely distinct 
mechanisms. 
Highly conserved nucleotide sequences, 
(TTGNNNGCTTCCAANNNTGGT) (SEQ ID NO: 4) and 
CCNCTTTTTG (SEQ ID NO: 5) have been found in the 5‘ 
?anking regions of alcohol oxidase, methanol oxidase, and 
dihydroxyacetone synthase genes in R pastoris, H. poly 
morpha and C. boia'ini S2. See Kumagai et al., US. Pat. No. 
5,641,661. It Was postulated that these conserved regions 
Were involved in binding methanol-speci?c trans-acting 
factors. HoWever, in a study characteriZing the AOX2 
promoter, these sequences Were not involved in transcrip 
tional regulation of the AOX2 gene since deletion of these 
regions did not impact regulation of the AOX2 promoter 
(Ohi, et al. (1994) Mol.Gen Genet 243:489—99). Thus, 
although these regions may be highly conserved across 
methylotrophic yeasts, their impact on transcriptional regu 
lation of the AOX genes remains to be fully elucidated. 
Accordingly, a need exists to identify promoters and other 
regulatory nucleotide sequences for the controlled expres 
sion and/or high level expression of heterologous proteins in 
yeast. In particular, a need exists to provide neW AOX1 
promoters and regulatory nucleotide sequences for the con 
trolled expression and/or high level expression of heterolo 
gous proteins in yeast. 
SUMMARY OF THE INVENTION 
Among the several aspects of the invention therefore is 
provided an isolated polynucleotide comprising a regulatory 
region containing a nucleotide sequence less than about 
1000 nucleotides long selected from the group consisting of: 
(a) SEQ ID NO: 16, a fragment of SEQ ID NO: 16, the 
complement of SEQ ID NO: 16, or a fragment of the 
complement of SEQ ID NO: 16; 
(b) a polynucleotide that hybridiZes to the polynucleotide 
of (a) under conditions of high stringency; and 
(c) a polynucleotide With at least 80% sequence homology 
to the polynucleotide of (a). 
Another aspect provides an isolated polynucleotide com 
prising a regulatory region containing a nucleotide sequence 
less than about 1000 nucleotides long selected from the 
group consisting of: 
(a) SEQ ID NO: 17, a fragment of SEQ ID NO: 17, the 
complement of SEQ ID NO: 17, or a fragment of the 
complement of SEQ ID NO: 17; 
(b) a polynucleotide that hybridiZes to the polynucleotide 
of (a) under conditions of high stringency; and 
(c) a polynucleotide With at least 80% sequence homology 
to the polynucleotide of (a). 
In yet another aspect is provided an isolated polynucle 
otide comprising a regulatory region containing a nucleotide 
sequence less than about 1000 nucleotides long selected 
from the group consisting of: 
(a) SEQ ID NO: 18, a fragment of SEQ ID NO: 18, the 
complement of SEQ ID NO: 18, or a fragment of the 
complement of SEQ ID NO: 18; 
(b) a polynucleotide that hybridiZes to the polynucleotide 
of (a) under conditions of high stringency; and 
(c) a polynucleotide With at least 80% sequence homology 
to the polynucleotide of (a). 
Still another aspect of the invention is provided an iso 
lated polynucleotide comprising a regulatory region con 
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taining a nucleotide sequence less than about 1000 nucle 
otides long selected from the group consisting of: 
(a) SEQ ID NO: 19, a fragment of SEQ ID NO: 19, the 
complement of SEQ ID NO: 19, or a fragment of the 
complement of SEQ ID NO: 19; 
(b) a polynucleotide that hybridiZes to the polynucleotide 
of (a) under conditions of high stringency; and 
(c) a polynucleotide With at least 80% sequence homology 
to the polynucleotide of (a). 
In yet a further aspect of the invention is provided an 
isolated polynucleotide comprising a regulatory region con 
taining a nucleotide sequence less than about 1000 nucle 
otides long selected from the group consisting of: 
(a) SEQ ID NO: 20, a fragment of SEQ ID NO: 20, the 
complement of SEQ ID NO: 20, or a fragment of the 
complement of SEQ ID NO: 20; 
(b) a polynucleotide that hybridiZes to the polynucleotide 
of (a) under conditions of high stringency; and 
(c) a polynucleotide With at least 80% sequence homology 
to the polynucleotide of (a). 
A further aspect of the invention provides an isolated 
polynucleotide comprising a regulatory region containing a 
nucleotide sequence less than about 1000 nucleotides long 
selected from the group consisting of: 
(a) SEQ ID NO: 21, a fragment of SEQ ID NO: 21, the 
complement of SEQ ID NO: 21, or a fragment of the 
complement of SEQ ID NO: 21; 
(b) a polynucleotide that hybridiZes to the polynucleotide 
of (a) under conditions of high stringency; and 
(c) a polynucleotide With at least 80% sequence homology 
to the polynucleotide of (a). 
Still another aspect of the invention provides a recombi 
nant vector comprising the polynucleotide of SEQ ID NO: 
16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ 
ID NO: 20, and SEQ ID NO: 21. Host cells comprising the 
recombinant vector are also provided. 
A further aspect provides an expression cassette compris 
ing the polynucleotide of SEQ ID NO: 16, SEQ ID NO: 17, 
SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ 
ID NO: 21. Host cells comprising the expression cassette are 
also provided. 
BRIEF DESCRIPTION OF THE DRAWINGS 
These and other features, aspects, and advantages of the 
present invention Will become better understood With regard 
to the folloWing description, appended claims, and accom 
panying ?gures Where: 
FIG. 1 depicts the construction of expression vector, 
pAL2 and mutagenesis vector pMMI101. PAL2 Was con 
structed by inserting Eco RI/Sma I fragment of pSAOHS 
into pIB1 promoterless vector. The vector pMMI101 Was 
constructed by inserting Eco RI/Bam HI fragment of 
pSAOHS into Eco RI/Bam. 
FIG. 2 depicts deletion analysis of the AOX1 promoter. 
The plasmids Were inserted into GS115 his4 locus. Single 
copy integrands Were identi?ed by Southern assay using 
HIS4 gene as a probe. The cells Were groWn in MM 
(induced) and MME (repressed) conditions. [3-Gal activity 
of the AOX1-lacZ fusion Was measured and reported as 
percent of activity of methanol-groWn cells containing 
pAL2. The TATA box is indicated by the black square, and 
+1 AT G is indicated by the upside doWn, black triangle. 
FIG. 3 depicts results of the gel shift assay for fragment 
A(SEQ ID NO: 16). Lane 1, no protein added; lane 2—5, six 
mg protein from MM groWn cells; lane 6, six mg protein 
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from MME grown cells; lane 3, thirty fold cold speci?c 
DNA (fragmentA(SEQ ID NO: 16)); lane 4, thirty fold cold 
fragment C (SEQ ID NO: 18); lane 5 thirty fold L. mono 
cytogeneses DNA. 
FIG. 4 depicts results of the gel shift assay for fragment 
C (SEQ ID NO: 18). Lane 1, no protein added; lanes 2—5, 
protein from MM groWn cells; lanes 7—9, protein from MME 
groWn cells; lane 3 and 7, thirty fold cold speci?c competitor 
(fragment C (SEQ ID NO: 18)); lanes 4 and 6, thirty fold 
cold unspeci?c competitor (fragment A (SEQ ID NO: 16)); 
lanes 5 and 9, thirty fold cold unspeci?c L. monocytogenes 
DNA. 
FIG. 5 depicts results of the gel shift assay for fragment 
F (SEQ ID NO: 21). Lane 1, no protein added; lane 2, six mg 
protein from MM groWn cells; lane 3, tWelve mg protein 
from MM groWn cells; lane 4, six mg protein from MME 
groWn cells; lane 5, tWelve mg protein from MME groWn 
cells. 
FIG. 6 depicts the consensus sequences of methanol 
regulated promoters of methylotrophic yeast. Occurrence of 
TTCCAA (A) (Kumagai et al., 1993) and GATAG (B) (Ohi 
et al., 1994) core consensus sequence in AOX1 promoter. C, 
Alignment of the MOX UAS2 With AOX1 promoter 
(Godecke et al., 1994). Minus numbers are given relative to 
+1 ATG codon, +/— de?nes plus/minus strand. The fragment 
letters containing the sequences are also given in the right 
column. 
ABBREVIATIONS AND DEFINITIONS 
To facilitate understanding of the invention, a number of 
terms and abbreviations as used herein are de?ned beloW: 
As used herein “isolated polynucleotide” means a poly 
nucleotide that is free of one or both of the nucleotide 
sequences Which ?ank the polynucleotide in the naturally 
occurring genome of the organism from Which the poly 
nucleotide is derived. The term includes, for example, a 
polynucleotide or fragment thereof that is incorporated in a 
vector or expression cassette; into an autonomously repli 
cating plasmid or virus; into the genomic DNA of a prokary 
ote or eukaryote; or that exists as a separate molecule 
independent of other polynucleotides. It also includes a 
recombinant chimeric polynucleotide that is part of a hybrid 
polynucleotide, for example, one encoding a polypeptide 
sequence. 
As used herein “polynucleotide” and “oligonucleotide” 
are used interchangeably and refer to a polymeric (2 or more 
monomers) form of nucleotides of any length, either ribo 
nucleotides or deoxyribonucleotides. Although nucleotides 
are usually joined by phosphodiester linkages, the term also 
includes polymeric nucleotides containing neutral amide 
backbone linkages composed of aminoethyl glycine units. 
This term refers only to the primary structure of the mol 
ecule. Thus, this term includes double- and single-stranded 
DNA and RNA. It also includes knoWn types of 
modi?cations, for example, labels, methylation, “caps”, 
substitution of one or more of the naturally occurring 
nucleotides With an analog, internucleotide modi?cations 
such as, for example, those With uncharged linkages (e.g., 
methyl phosphonates, phosphotriesters, phosphoamidates, 
carbamates, etc.), those containing pendant moieties, such 
as, for example, proteins (including for e.g., nucleases, 
toxins, antibodies, signal peptides, poly-L-lysine, etc.), 
those With intercalators (e.g., acridine, psoralen, etc.), those 
containing chelators (e.g., metals, radioactive metals, boron, 
oxidative metals, etc.), those containing alkylators, those 
With modi?ed linkages (e.g., alpha anomeric nucleic acids, 
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etc.), as Well as unmodi?ed forms of the polynucleotide. 
Polynucleotides include both sense and antisense strands. 
As used herein, “sequence” means the linear order in 
Which monomers occur in a polymer, for example, the order 
of amino acids in a polypeptide or the order of nucleotides 
in a polynucleotide. 
As used herein, the terms “complementary” or “comple 
mentarity” refer to the pairing of bases, purines and 
pyrimidines, that associate through hydrogen bonding in 
double stranded nucleic acid. The folloWing base pairs are 
complementary: guanine and cytosine; adenine and thym 
ine; and adenine and uracil. The terms as used herein include 
complete and partial complementarity. 
As used herein, the term “hybridization” refers to a 
process in Which a strand of nucleic acid joins With a 
complementary strand through base pairing. The conditions 
employed in the hybridiZation of tWo non-identical, but very 
similar, complementary nucleic acids varies With the degree 
of complementarity of the tWo strands and the length of the 
strands. Thus the term contemplates partial as Well as 
complete hybridiZation. Such techniques and conditions are 
Well knoWn to practitioners in this ?eld. 
As used herein, “expression cassette” means a genetic 
module comprising a gene and the regulatory regions nec 
essary for its expression, Which may be incorporated into a 
vector. 
As used herein, “secretion sequence” or “signal peptide” 
or “signal sequence” means a sequence that directs neWly 
synthesiZed secretory or membrane proteins to and through 
membranes of the endoplasmic reticulum, or from the cyto 
plasm to the periplasm across the inner membrane of 
bacteria, or from the matrix of mitochondria into the inner 
space, or from the stroma of chloroplasts into the thylakoid. 
Fusion of such a sequence to a gene that is to be expressed 
in a heterologous host ensures secretion of the recombinant 
protein from the host cell. 
As used herein, “operably linked” means any linkage, 
irrespective of orientation or distance, betWeen a regulatory 
sequence and coding sequence, Where the linkage permits 
the regulatory sequence to control expression of the coding 
sequence. 
As used herein, “heterologous coding sequence” means 
any coding sequence other than the one that naturally 
encodes the alcohol oxidase 1 protein, or any homolog of the 
alcohol oxidase 1 protein. 
As used herein, “regulatory sequence” or “regulatory 
region” as used in reference to a speci?c gene refers to the 
coding or non-coding nucleotide sequences Within that gene 
that are necessary or suf?cient to provide for the regulated 
expression of the coding region of a gene. Thus, the term 
encompasses promoter sequences, regulatory protein bind 
ing sites, upstream activator sequences and the like. Speci?c 
nucleotides Within a regulatory region may serve multiple 
functions. For example, a speci?c nucleotide may be part of 
a promoter and participate in the binding of a transcriptional 
activator protein. 
As used herein, “coding region” refers to that portion of 
a gene Which codes for a protein. The term “non-coding 
region” refers to that portion of a gene that is not a coding 
region. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Applicants have identi?ed regulatory nucleotide 
sequences that are part of the non-coding region of the 
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alcohol oXidase 1 (“AOX1”) gene. The AOX1 gene encodes 
the enzyme alcohol oXidase 1, Which catalyzes the oxidation 
of methanol to formaldehyde (as stated in more detail 
above). The AOX1 promoter, is an inducible promoter, and 
is primarily induced by methanol and carbon starvation, and 
repressed in response to glucose and ethanol. Although the 
AOX1 promoter has been identi?ed (SEQ ID NO: 1), prior 
to applicants discovery, 5‘ regulatory nucleotide sequences 
Within the promoter region had not been characteriZed. The 
regulatory regions discovered by applicants, as set-forth 
herein, may be employed to increase the eXpression of genes 
of interest in a variety of cells. 
In order to identify the regulatory regions of the present 
invention, applicants divided the 1052 base pair AOX1 
promoter (SEQ ID NO: 1) into siX fragments, A (SEQ ID 
NO: 16), B (SEQ ID NO: 17), C (SEQ ID NO: 18), D (SEQ 
ID NO: 19), E (SEQ ID NO: 20), and F (SEQ ID NO: 21). 
Through a series of systematic deletions comprising both 
sequential deletions and dropout mutations, in conjunction 
With gel shift assays, regions of the AOX1 promoter (SEQ 
ID NO: 1) element involved in regulation and DNA-protein 
interactions Were identi?ed (as set-forth in more detail in the 
eXample section beloW). Based upon this deletion analysis, 
as depicted in FIG. 2, fragments A (SEQ ID NO: 16), B 
(SEQ ID NO: 17), C (SEQ ID NO: 18), E (SEQ ID NO: 20), 
and F (SEQ ID NO: 21) contain positive regulatory sites, 
While fragment D (SEQ ID NO: 19) contains a negative 
regulatory site. In addition, based upon gel shift assays, as 
depicted in FIG. 3 and FIG. 4, it is believed that fragments 
A (SEQ ID NO: 16), and C (SEQ ID NO: 18) contain 
sequences for different DNA-binding proteins. It should be 
noted that, speci?c nucleotides Within a regulatory region 
may serve multiple functions. For example, a speci?c nucle 
otide may be part of a promoter and participate in the 
binding of a transcriptional activator protein. Thus, While 
applicants believe that A(SEQ ID NO: 16), B (SEQ ID NO: 
17), C (SEQ ID NO: 18), E (SEQ ID NO: 20), and F (SEQ 
ID NO: 21) contain positive regulatory sites, and fragment 
D (SEQ ID NO: 19) contains a negative regulatory site, in 
addition to the stated function, each of these regulatory 
regions may serve multiple regulatory functions. 
The present invention, therefore, encompasses an isolated 
polynucleotide comprising a regulatory region containing 
SEQ ID NO: 16, a fragment of SEQ ID NO: 16, the 
complement of SEQ ID NO: 16, or a fragment of the 
complement of SEQ ID NO: 16. In one embodiment the 
polynucleotide (or the fragment, or the complement of either 
the polynucleotide or fragment) is less than about 1000 
nucleotides long, in another embodiment the polynucleotide 
is betWeen about 4 nucleotides to about 750 nucleotides 
long. More preferably, hoWever, the polynucleotide is 
betWeen about 250 nucleotides to about 750 nucleotides 
long. The fragments may be employed as probes for SEQ ID 
NO: 16 or related sequences. Also included are isolated 
polynucleotides that hybridiZe to SEQ ID NO: 16, or the 
complement of SEQ ID NO: 16 under conditions of high 
stringency. In one embodiment these polynucleotides are 
less than about 1000 nucleotides long, in another embodi 
ment these polynucleotides are betWeen about 4 nucleotides 
to about 750 nucleotides long. Such polynucleotides may be 
used as probes for SEQ ID NO: 16 or related sequences. 
Still another embodiment provides an isolated polynucle 
otide comprising a regulatory region containing SEQ ID 
NO: 17, a fragment of SEQ ID NO: 17, the complement of 
SEQ ID NO: 17, or a fragment of the complement of SEQ 
ID NO: 17. In one embodiment the polynucleotide (or the 
fragment, or the complement of either the polynucleotide or 
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fragment) is less than about 1000 nucleotides long, in 
another embodiment the polynucleotide is betWeen about 4 
nucleotides to about 750 nucleotides long. More preferably, 
hoWever, the polynucleotide is betWeen about 250 nucle 
otides to about 750 nucleotides long. The fragments may be 
employed as probes for SEQ ID NO: 17 or related 
sequences. Also included are isolated polynucleotides that 
hybridiZe to SEQ ID NO: 17, or the complement of SEQ ID 
NO: 17 under conditions of high stringency. In one embodi 
ment these polynucleotides are less than about 1000 nucle 
otides long, in another embodiment these polynucleotides 
are betWeen about 4 nucleotides to about 750 nucleotides 
long. Such polynucleotides may be used as probes for SEQ 
ID NO: 17 or related sequences. 
In yet another embodiment, the invention encompasses an 
isolated polynucleotide comprising a regulatory region con 
taining SEQ ID NO: 18, a fragment of SEQ ID NO: 18, the 
complement of SEQ ID NO: 18, or a fragment of the 
complement of SEQ ID NO: 18. In one embodiment the 
polynucleotide (or the fragment, or the complement of either 
the polynucleotide or fragment) is less than about 1000 
nucleotides long, in another embodiment the polynucleotide 
is betWeen about 4 nucleotides to about 750 nucleotides 
long. More preferably, hoWever, the polynucleotide is 
betWeen about 250 nucleotides to about 750 nucleotides 
long. The fragments may be employed as probes for SEQ ID 
NO: 18 or related sequences. Also included are isolated 
polynucleotides that hybridiZe to SEQ ID NO: 18, or the 
complement of SEQ ID NO: 18 under conditions of high 
stringency (as de?ned herein). In one embodiment these 
polynucleotides are less than about 1000 nucleotides long, in 
another embodiment these polynucleotides are betWeen 
about 4 nucleotides to about 750 nucleotides. Such poly 
nucleotides may be used as probes for SEQ ID NO: 18 or 
related sequences. 
An additional embodiment provides an isolated poly 
nucleotide comprising a regulatory region containing SEQ 
ID NO: 19, a fragment of SEQ ID NO: 19, the complement 
of SEQ ID NO: 19, or a fragment of the complement of SEQ 
ID NO: 19. In one embodiment the polynucleotide (or the 
fragment, or the complement of either the polynucleotide or 
fragment) is less than about 1000 nucleotides long, in 
another embodiment the polynucleotide is betWeen about 4 
nucleotides to about 750 nucleotides long. More preferably, 
hoWever, the polynucleotide is betWeen about 250 nucle 
otides to about 750 nucleotides long. The fragments may be 
employed as probes for SEQ ID NO: 19 or related 
sequences. Also included are isolated polynucleotides that 
hybridiZe to SEQ ID NO: 19, or the complement of SEQ ID 
NO: 19 under conditions of high stringency. In one embodi 
ment these polynucleotides are less than about 1000 nucle 
otides long, in another embodiment these polynucleotides 
are betWeen about 4 nucleotides to about 750 nucleotides. 
Such polynucleotides may be used as probes for SEQ ID 
NO: 19 or related sequences. 
In yet another embodiment, the invention encompasses an 
isolated polynucleotide comprising a regulatory region con 
taining SEQ ID NO: 20, a fragment of SEQ ID NO: 20, the 
complement of SEQ ID NO: 20, or a fragment of the 
complement of SEQ ID NO: 20. In one embodiment the 
polynucleotide (or the fragment, or the complement of either 
the polynucleotide or fragment) is less than about 1000 
nucleotides long, in another embodiment the polynucleotide 
is betWeen about 4 nucleotides to about 750 nucleotides 
long. More preferably, hoWever, the polynucleotide is 
betWeen about 250 nucleotides to about 750 nucleotides 
long. The fragments may be employed as probes for SEQ ID 
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NO: 20 or related sequences. Also included are isolated 
polynucleotides that hybridize to SEQ ID NO: 20, or the 
complement of SEQ ID NO: 20 under conditions of high 
stringency. In one embodiment these polynucleotides are 
less than about 1000 nucleotides long, in another embodi 
ment these polynucleotides are betWeen about 4 nucleotides 
to about 750 nucleotides long. Such polynucleotides may be 
used as probes for SEQ ID NO: 20 or related sequences. 
A further embodiment of the present invention provides 
an isolated polynucleotide comprising a regulatory region 
containing SEQ ID NO: 21, a fragment of SEQ ID NO: 21, 
the complement of SEQ ID NO: 21, or a fragment of the 
complement of SEQ ID NO: 21. In one embodiment the 
polynucleotide (or the fragment, or the complement of either 
the polynucleotide or fragment) is less than about 1000 
nucleotides long, in another embodiment the polynucleotide 
is betWeen about 4 nucleotides to about 750 nucleotides 
long. More preferably, hoWever, the polynucleotide is 
betWeen about 250 nucleotides to about 750 nucleotides 
long. The fragments may be employed as probes for SEQ ID 
NO: 21 or related sequences. Also included are isolated 
polynucleotides that hybridiZe to SEQ ID NO: 21, or the 
complement of SEQ ID NO: 21 under conditions of high 
stringency. In one embodiment these polynucleotides are 
less than about 1000 nucleotides long, in another embodi 
ment these polynucleotides are betWeen about 4 nucleotides 
to about 750 nucleotides long. Such polynucleotides may be 
used as probes for SEQ ID NO: 21 or related sequences. 
As is Well knoWn in the art, stringency is related to the Tm 
of the hybrid formed. The Tm (melting temperature) of a 
nucleic acid hybrid is the temperature at Which 50% of the 
bases are base-paired. For example, if one the partners in a 
hybrid is a short oligonucleotide of approximately 20 bases, 
50% of the duplexes are typically strand separated at the Tm. 
In this case, the Tm re?ects a time-independent equilibrium 
that depends on the concentration of oligonucleotide. In 
contrast, if both strands are longer, the Tm corresponds to a 
situation in Which the strands are held together in structure 
possibly containing alternating duplex and denatured 
regions. In this case, the Tm re?ects an intramolecular 
equilibrium that is independent of time and polynucleotide 
concentration. 
As is also Well knoWn in the art, Tm is dependent on the 
composition of the polynucleotide (e.g. length, type of 
duplex, base composition, and extent of precise base 
pairing) and the composition of the solvent (e.g. salt con 
centration and the presence of denaturants such formamide). 
An equation for the calculation of Tm can be found in 
Sambrook et al. (Molecular Cloning, 2nd ed., Cold Spring 
Harbor Press, 1989) and is: 
Where L is the length of the hybrid in base pairs, the 
concentration of Na+ is in the range of 0.01M to 0.4M and 
the G+C content is in the range of 30% to 75%. Equations 
for hybrids involving RNA can be found in the same 
reference. Alternative equations can be found in Davis et al., 
Basic Methods in Molecular Biology, 2nd ed., Appleton and 
Lange, 1994, Sec 6—8. 
Methods for hybridiZation and Washing are Well knoWn in 
the art and can be found in standard references in molecular 
biology such as those cited herein. In general, hybridiZations 
are usually carried out in solutions of high ionic strength 
(6><SSC or 6><SSPE) at a temperature 20—25° C. beloW the 
Tm. High stringency Wash conditions are often determined 
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empirically in preliminary experiments, but usually involve 
a combination of salt and temperature that is approximately 
12—20° C. beloW the Tm. One example of high stringency 
conditions is 1><SSC at 60° C. Another example of high 
stringency Wash conditions is 0.1><SSPE, 0.1% SDS at 42° 
C. (Meinkoth and Wahl, Anal. Biochem., 138:267—284, 
1984). An example of even higher stringency Wash condi 
tions is 0.1><SSPE, 0.1% SDS at 50—65° C. In one preferred 
embodiment, high stringency Washing is carried out under 
conditions of 1><SSC and 60° C. 
In another embodiment, the present invention provides an 
isolated polynucleotide sequence With at least 80%, more 
preferably 90%, more preferably still 95%, even more 
preferably 97% and still more preferably 99% sequence 
homology to SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 
18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO 21 or 
the complement of SEQ ID NO: 16, SEQ ID NO: 17, SEQ 
ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO 
21. 
“Homology”, as is Well understood in the art, is a rela 
tionship betWeen tWo or more polypeptide sequences or tWo 
or more polynucleotide sequences, as determined by com 
paring the sequences. In the art, “homology” also means the 
degree of sequence relatedness betWeen polypeptide or 
polynucleotide sequences, as determined by the match 
betWeen strings of such sequences. “Homology” can be 
readily calculated by knoWn methods including, but not 
limited to, those described in Computational Molecular 
Biology, Lesk, A. M., ed., Oxford University Press, NeW 
York (1988); Biocomputing: Informatics and Genome 
Projects, Smith, D. W., ed., Academic Press, NeW York, 
1993,‘ Computer Analysis of Sequence Data, Part I, Griffin, 
A. M. and Grif?n, H. G., eds., Humana Press, NeW Jersey 
(1994); Sequence Analysis in Molecular Biology, von 
Heinje, G., Academic Press (1987); Sequence Analysis 
Primer, Gribskov, M. and Devereux, J ., eds., Stockton Press, 
NeW York (1991); and Carillo, H., and Lipman, D., SIAMJ 
Applied Math, 48:1073 (1988). Methods to determine 
homology are designed to give the largest match betWeen the 
sequences tested. Moreover, methods to determine homol 
ogy are codi?ed in publicly available programs. Computer 
programs Which can be used to determine identity/homology 
betWeen tWo sequences include, but are not limited to, GCG 
(Devereux, J., et al., Nucleic Acids Research 12(1):387 
(1984); suite of ?ve BLAST programs, three designed for 
nucleotide sequences queries (BLASTN, BLASTX, and 
TBLASTX) and tWo designed for protein sequence queries 
(BLASTP and TBLASTN) (Coulson, Trends in 
Biotechnology, 12: 76—80 (1994); Birren, et al., Genome 
Analysis, 1: 543—559 (1997)). The BLAST X program is 
publicly available from NCBI and other sources (BLAST 
Manual, Altschul, S., et al., NCBI NLM NIH, Bethesda, Md. 
20894; Altschul, S., et al., J. Mol. Biol., 215:403—410 
(1990)). The Well knoWn Smith Waterman algorithm can 
also be used to determine homology. 
The isolated polynucleotide comprising the regulatory 
region of the present invention, Without being bound by any 
particular limitation, may comprise any combination of SEQ 
ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 
19, SEQ ID NO: 20, and SEQ ID NO: 21 or a fragment of 
any of these sequences. Additionally, the regulatory region 
may comprise any combination of the complement of SEQ 
ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 
19, SEQ ID NO: 20, and SEQ ID NO: 21 or a fragment of 
the complement of any of these sequences. The regulatory 
region, may also comprise any combination of isolated 
polynucleotides that hybridiZe under conditions of high 
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stringency to SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 
18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21 
or that hybridize under conditions of high stringency to the 
complement of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID 
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 
21. Furthermore, the regulatory region, may comprise any 
combination of isolated polynucleotides With at least 80% 
sequence homology to SEQ ID NO: 16, SEQ ID NO: 17, 
SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ 
ID NO: 21 or the complement of SEQ ID NO: 16, SEQ ID 
NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, 
and SEQ ID NO: 21. Accordingly, for example, in one 
embodiment of the present invention, the regulatory region 
comprises SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 
18, from 1 to about 3 copies of SEQ ID NO: 20, and SEQ 
ID NO: 21. In yet another embodiment, the regulatory 
region comprises SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID 
NO: 20, and SEQ ID NO: 21. 
The polynucleotides comprising regulatory regions of the 
present invention may be isolated by any method generally 
knoWn in the art for isolating non-coding regions of nucleic 
acid sequence. One such method comprises employing 
hybridiZation of a probe to a genomic library to detect shared 
nucleotide sequence and is detailed in, for example, Sam 
brook et al., Molecular Cloning, A Laboratory Manual, 2nd 
ed., Cold Spring Harbor Laboratory Press, (1989) and 
Ausubel et al., Short Protocols in Molecular Biology, 3rd 
ed., John Wiley & Sons (1995). 
Also included are vectors comprising the isolated poly 
nucleotide regulatory sequences of the invention or the 
complement thereof, as set-forth in detail above. Any vector 
suitable for propagation in yeast may be employed such as, 
for example, pIB1 (Sears et al., (1998) Yeast 14: 783—90), 
pPICZ (commercially available through Invitrogen, 
Carlsbad, Calif.) vector series, and pPIC9K (commercially 
available through Invitrogen, Carlsbad, Calif.). The vector 
may also be either a cloning vector or an expression vector. 
A cloning vector is a self-replicating DNA molecule that 
serves to maintain a DNA segment into a host cell. The most 
common type of cloning vectors are bacterial plasmids. An 
expression vector is a cloning vector designed so that a 
sequence inserted at a particular site Will be transcribed into 
mRNA and in addition may be translated into a protein. Both 
cloning and expression vectors usually contain nucleotide 
sequences that alloW the vectors to replicate in one or more 
suitable host cells. In cloning vectors, this sequence is 
generally one that enables the vector to replicate indepen 
dently of the host cell chromosomes, and also includes either 
origins of replication or autonomously replicating 
sequences. Various bacterial and yeast origins of replication 
are Well knoWn to those skilled in the art and include, but are 
not limited to, the pBR322 plasmid origin, and the 2 
uplasmid origin. Ausubel et al., ed., Short Protocols in 
Molecular Biology, 3rd ed., Wiley & Sons, 1995. 
The isolated polynucleotide comprising regulatory 
sequences of the present invention may be inserted into the 
vector by a variety of methods. In yet a further embodiment, 
the isolated polynucleotide comprising regulatory regions 
operably linked to a heterologous coding region may be 
inserted into the vector. In the most common method, the 
sequence is inserted into an appropriate restriction endonu 
clease site(s) using procedures commonly knoWn to those 
skilled in the art and detailed in, for example, Sambrook et 
al., Molecular Cloning, A Laboratory Manual, 2nd ed., Cold 
Spring Harbor Laboratory Press, (1989) and Ausubel et al., 
Short Protocols in Molecular Biology, 3rd ed., John Wiley & 
Sons (1995). 
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Expression and cloning vectors can and usually do con 
tain a selection gene or selection marker. Typically, this gene 
encodes a protein necessary for the survival or groWth of the 
host cell transformed With the vector. Examples of suitable 
selection markers include, HIS4, ARG4, ble, and kan (Cregg 
et al., (2000) Mol. Biotech. 16: 23—52). The selection marker 
can have its oWn promoter so that expression of the marker 
occurs independent of the polynucleotide construct. The 
marker promoter can be either a constitutive or an inducible 
promoter. 
In a further embodiment, the vector of the present inven 
tion also typically Will include a sequence that is homolo 
gous With the host’s sequence at a particular gene loci, for 
example a portion of the His4 gene or AOX gene (both yeast 
genes), to enable the vector to insert into the host’s chro 
mosome by homologous recombination. Preferably, the 
homologous sequence employed in the invention Will be at 
least approximately 200 nucleotides in length and have 
homology to yeast genomic DNA. Applicants have found 
that such integration is desirable, particularly When the host 
is P pastoris, because vectors that are not integrated tend to 
be unstable. 
More particularly, in another embodiment is provided a 
recombinant polynucleotide comprising any of the above 
described regulatory regions of the invention operably 
linked to a heterologous coding region. Such recombinant 
polynucleotides are commonly employed in cloning or 
expression vectors (as detailed above), although other uses 
are possible. The heterologous coding region may encode 
any protein of interest suitable for expression in the host cell 
such as enZymes, hormones, regulatory proteins, structural 
proteins, or antigens (for use in inducing an immune 
response). 
The isolated polynucleotides of the present invention may 
be part of an expression cassette that minimally comprises, 
operably linked in 5‘ to 3‘ direction, a polynucleotide com 
prising a regulatory region of the present invention, a 
heterologous coding region and a transcriptional termination 
signal sequence functional in a host cell. The expression 
cassette may comprise any of the isolated polynucleotide 
regulatory regions of the invention, as previously discussed. 
Additionally, the heterologous coding region may encode 
any protein of interest suitable for expression in the host cell 
such as enZymes, hormones, regulatory proteins, structural 
proteins, or antigens (for use in inducing an immune 
response). 
In a further embodiment, the expression cassette can also 
comprise an operably linked targeting sequence, transit or 
secretion peptide coding region capable of directing trans 
port of the protein produced to the desired location. The 
expression cassette may also further comprise a nucleotide 
sequence encoding a selectable marker and/or a puri?cation 
moiety. Various methods have been devised for the addition 
of such af?nity puri?cation moieties to proteins. Represen 
tative examples can be found in US. Pat. Nos. 4,703,004, 
4,782,137, 4,845,341, 5,935,824, and 5,594,115. Any 
method knoWn in the art for the addition of nucleotide 
sequences encoding puri?cation moieties can be used for 
example those contained in Innis et al., PCR Protocols, 
Academic Press (1990) and Sambrook et al., Molecular 
Cloning, 2nd ed., Cold Spring Harbor Laboratory Press 
(1989). In yet another embodiment, the expression cassette 
can comprise a sequence that is homologous With the host’s 
sequence at a particular gene loci to enable the cassette to 
insert into the host’s chromosome by homologous recom 
bination. 
Encompassed Within the present invention are host cells 
transformed With any of the constructs described herein 
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comprising the polynucleotide regulatory sequences of the 
invention. The host cell is preferably a yeast cell. Yeast are 
preferred hosts because their usage provides a means to 
regulate gene expression When the regulatory sequences of 
the invention are employed. As stated above, the regulatory 
regions of the invention are repressible in response to 
repressing carbon sources (eg glucose, ethanol, fructose, 
galactose, sucrose and glycerol) and inducible in response to 
non-repressing carbon sources (eg sorbital, mannitol, 
threhalose, and alanine) When subjecting the transformed 
yeast to carbon starvation. Accordingly, gene expression can 
be strictly regulated based upon the medium selected to 
groW the cells. 
Even more preferably, hoWever, the host Will be a methy 
lotrophic yeast cell. Still more preferably, the methy 
lotrophic yeast cell is selected from the group of genera 
consisting of Hansenula, Candida, Torulopsis and Pichia. 
Even more preferably, the yeast cell is from R pastoris. The 
use of methylotrophic yeast provides an additional means to 
control gene expression When employing the regulatory 
regions of the invention. Methylotrophic yeast, as opposed 
to yeast in general, are capable of groWth on methanol as 
their sole carbon and energy source. In addition, as delin 
eated above, methanol is a strong inducer of the regulatory 
sequences of the invention. For example, in methanol groWn 
R pastoris cells, AOX rapidly accumulates up to 30% of the 
total soluble protein. Thus, the use of methylotrophic yeast 
as host cells in the present invention provides a mechanism 
to both reliably control gene expression and at the same 
time, achieve a high rate of expression. Introduction of the 
construct into the host cell can be accomplished by any 
method knoWn in the art. 
The present invention also includes methods for the 
production of proteins from the above described host cells 
transformed With any of the constructs characteriZed herein 
containing the polynucleotide regulatory regions of the 
present invention operably linked to a gene encoding the 
desired protein. Proteins can be expressed in any suitable 
host cells, but are preferably expressed in yeast host cells for 
the reasons previously identi?ed. Host cells are genetically 
transformed to produce the protein of interest by introduc 
tion of an expression vector containing the nucleic acid 
sequence of interest. The characteristics of suitable cloning 
vectors and the methods for their introduction into host cells 
have been previously discussed. Methods for such protein 
production are knoWn to those skilled in the art. (Davis et al., 
Basic Methods in Molecular Biology, Elsevier Science Pub 
lishing (1986); Ausubel et al., Short Protocols in Molecular 
Biology, 2”d Ed., John Wiley & Sons (1992)). 
Host cells are groWn under appropriate conditions to a 
suitable cell density to optimiZe expression of the protein. If 
the protein accumulates in the host cell, the cells are 
harvested by, for example, centrifugation or ?ltration. The 
cells are then disrupted by physical or chemical means to 
release the protein into the cell extract from Which the 
protein can be puri?ed. If the host cells secrete the protein 
into the medium, the cells and medium are separated and the 
medium retained for puri?cation of the protein. 
Larger quantities of protein can be obtained from cells 
carrying ampli?ed copies of the sequence of interest. In this 
method, the sequence is contained in a vector that carries a 
selectable marker and transfected into the host cell or the 
selectable marker is co-transfected into the host cell along 
With the sequence of interest. Lines of host cells are then 
selected in Which the number of copies of the sequence have 
been ampli?ed. Anumber of suitable selectable markers Will 
be readily apparent to those skilled in the art. For example, 
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the sh ble gene is Widely used as a maker for 
co-ampli?cation. The sh ble gene product confers resistance 
to the drug Zeocin in both E. coli and yeast. 
Proteins recovered can be puri?ed by a variety of com 
monly used methods, including, but not limited to, ammo 
nium sulfate precipitation, immuno precipitation, ethanol or 
acetone precipitation, acid extraction, ion exchange 
chromatography, siZe exclusion chromatography, affinity 
chromatography, high performance liquid chromatography, 
electrophoresis, and ultra ?ltration. If required, protein 
refolding systems can be used to complete the con?guration 
of the protein. 
The polynucleotide encoding the regulatory sequences of 
the invention, as described in detail above, may be employed 
to increase the expression of genes of interest in a variety of 
host cells. HoWever, applicants discovery, in addition to 
increased gene expression, may also be employed for a 
number of other functions. For example, the regulatory 
sequences of the invention may be employed in a research 
setting to further characteriZe promoter function and to study 
peroxisome biogenesis. 
The detailed description set-forth above is provided to aid 
those skilled in the art in practicing the present invention. 
Even so, this detailed description should not be construed to 
unduly limit the present invention as modi?cations and 
variation in the embodiments discussed herein can be made 
by those of ordinary skill in the art Without departing from 
the spirit or scope of the present inventive discovery. 
All publications, patents, patent applications and other 
references cited in this application are herein incorporated 
by reference in their entirety as if each individual 
publication, patent, patent application or other reference 
Were speci?cally and individually indicated to be incorpo 
rated by reference. 
Without further elaboration, it is believed that one skilled 
in the art can, using the preceding description, utiliZe the 
present invention to its fullest extent. The folloWing pre 
ferred speci?c embodiments are, therefore, to be construed 
as merely illustrative, and not imitative of the remainder of 
the disclosure in any Way Whatsoever. 
EXAMPLE 
Materials and Methods 
Strains and Plasmids. 
Plasmid pSAOH5 (Tschopp et al., (1987) Nucleic Acids 
Res. 15: 3859—76) and R pastoris GS115 (Tschopp et al., 
(1987) Nucleic Acids Res. 15 : 3859—76) (his4) strain Were 
the generous gift of J. M. Cregg, Keck Graduate Institute, 
Claremont, Calif. pIB1 promoter less expression vector Was 
provided by B. S. Glick (University of Chicago, Chicago, 
111.). E. coli strains JM109 (endA1, recA1, gyrA96, thi, 
hsdR17(rk_, mk+), relA1, supE44, l', D(lac_proAB), [F‘, 
traD36, proA+B+, lacIqZDM15] and ES1301 mutS (LacZ53, 
mutS201::Tn5, thyA36, rha'5, metB1, deoC,IN (rrnD-rrnE), 
pALTER®-1 plasmid Were purchased as a components of 
Altered Sites® II in vitro Mutagenesis System (Promega, 
Madison, Wis.). 
Media, groWth conditions and enZymatic analysis. Yeasts 
Were groWn in minimal glycerol media (MGY: 1.34% yeast 
nitrogen base Without amino acids, 1% glycerol, 4><10_5% 
biotin) and transformed cells Were selected on Minimal 
Dextrose (MD) plates (1.34% yeast nitrogen base Without 
amino acids (YNB), 2% glucose, 4><10_5% biotin and 1.5% 
agar). If required 0.0004% histidine Was added to the media. 
The cells Were groWn on Minimal Methanol (MM, 1.34% 
YNB, 4><10_5% biotin, 0.5% methanol) and Minimal 
Methanol-Ethanol (MME, 1.34% YNB, 4><10_5% biotin, 
0.5% methanol and 0.5% ethanol) until the optical density 
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(600 nm) reached to 1.5—2.0 at 30° C. [3-Gal activity Was 
assayed using ONPG (o-Nitrophyenyl B-D 
glactopyranoside) as reported by Miller, J. H. Assay of 
[3-galactosidase. in Miller, J. H. (ed), Experiments in 
Molecular Genetic, Cold Spring Harbor Laboratory, pp. 
352—355 (1972) incorporating the modi?cation proposed by 
Guarente and Ptashne, Fusion of Escherichia coli lacZ to the 
cytochrome c gene of Saccharomyces cerevisiae. Proc. Natl. 
Acad. Sci. USA 78, 2199—203 (1981). The cells Were per 
meabiliZed With chloroform and sodium dodecyl sulfate 
(SDS) and the results Were reported in Miller Units. 
General DNA Techniques. 
Restriction enZymes and primers Were from NeW England 
Biolabs Inc. (Beverly, Mass.), Site Directed Mutagenesis 
(SDM) Was performed With the Altered Sites® II in vitro 
Mutagenesis System from Promega (Madison, Wis.) accord 
ing to the manufacturer’s recommendations. Primers Were 
purchased from Sigma/Genosys (The Woodlands, Tex.). 
Protocols for the system Were folloWed as described in the 
technical manual. All other DNA manipulations Were as 
previously described (Sambrook, et al., (1989) Molecular 
Cloning: A Laboratory Manual). A 1.5 Kb HIS4 fragment 
from pAL2 Was used for Southern analysis to select single 
copy transformants. 
Plasmid Constructions. 
The plasmid pSAOH5 Was ?rst used as the parental 
plasmid to characteriZe the regulation of LacZ gene under 
the control of the AOX1 promoter of R pastoris. pAL2, an 
integrating plasmid, Was constructed because of instability 
of the plasmid pSAOH5 in R pastoris. The 3.6 kb Eco 
RI-Nru I fragment of pSAOH5 Was inserted in the Eco 
RI-Sma I region of the pIB1, promoter less Pichia expres 
sion vector, and pAL2 parental plasmid Was obtained. The 
Eco RI/Nru I fragment of pSAOH5 contained the 5‘ untrans 
lated region and ?rst 15 amino acids of AOX1 fused to the 
lacZ gene at codon nine. The mutagenesis plasmid, 
pMMI101, Was constructed by inserting a 1120 base pair 
Eco RI-Bam HI fragment of pSAOH5 into pALTER-1 (FIG. 
1). 
The plasmids containing 5‘ deletion derivatives of the 
AOX1 promoter Were constructed using the Altered Sites® 
II in vitro Mutagenesis System to insert Eco RI sites at 
various positions along the promoter element. The primers 
used to obtain 5‘ deletion derivatives of the AOX1 promoter 
are as folloWs; 
AOXRI132 
5'—ACGCAGGAATTCCTCCACTC—3' (SEQ ID NO: 22) 
AoxRI285 
5'—GGCGAGGAATTCATGTTTGT—3' (SEQ ID NO: 23) 
AoxRI424 
5'—GTCTTGGAATTCCTAATATGAC—3' (SEQ ID NO: 24) 
AOXRI551 
5'—GGTATTGAATTCACGAATGCTC—3' (SEQ ID NO: 25) 
AOXRI699 
5'—CTTCCAAGAATTCTGGTGGG—3' (SEQ ID NO: 26) 
The mutant plasmids (pMMI132-pMMI669) Were 
digested With Eco RI/Sma I, and the fragments Were 
exchanged With the native AOX1 promoter in pAL2. 
The construction of PALD series Which remove internal 
AOX1 promoter sequences Was as folloWs: PMMI series of 
plasmids, pMMI132, pMMI285, pMMI424 and pMMI551 
Which carry the mutant Eco RI sites and deletes the 5‘ 
upstream AOX1 promoter fragments, A (SEQ ID NO: 16), 
AB (SEQ ID NO: 16 and SEQ ID NO: 17, respectively), 
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ABC (SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 
18, respectively) ABCD (SEQ ID NO: 16, SEQ ID NO: 17, 
SEQ ID NO: 18, and SEQ ID NO: 19, respectively), 
respectively. These fragments Were inserted into the expres 
sion plasmids carrying the sequential deletion derivatives of 
the AOX1 promoter, pAL285, pAL424, pAL551, pAL669, 
and the plasmids Were named pALD1, pALD2, pALD3 and 
pALD4, respectively. Consequently each PALD plasmid 
lacks B (SEQ ID NO: 17), C (SEQ ID NO: 18), D (SEQ ID 
NO: 19) and E (SEQ ID NO: 20) promoter fragments 
respectively. 
In order to purify the regions of the fragments (B (SEQ ID 
NO: 17), C (SEQ ID NO: 18), D (SEQ ID NO: 19) and E 
(SEQ ID NO: 20)) for band shift assay, a second round of 
site directed mutagenesis Was done. The pMMI132, 
pMMI285, pMMI424, pMMI551 ssDNAs and AOXRI285, 
AOXRi424, AOXRI551 and AOXR1669 primers Were used 
for SDM (site directed mutagenesis) reactions to drop B 
(SEQ ID NO: 17), C (SEQ ID NO: 18), D (SEQ ID NO: 19) 
and E (SEQ ID NO: 20) fragment, respectively. For 
example, to purify fragment B (SEQ ID NO: 17), pMMI132 
single stranded DNA and primer AOX1285 Were used to 
insert a third EcoRI site into the AOX1 promoter. After sited 
directed mutagenesis, each of fragments A (SEQ ID NO: 
16), B (SEQ ID NO: 17), C (SEQ ID NO: 18), D (SEQ ID 
NO: 19), E (SEQ ID NO: 20) and F (SEQ ID NO: 21) Was 
gel puri?ed With a Gene Clean II Kit (Bio101, Inc. Vista, 
Calif.). 
Prior to transformation, the deletion and chimen c plas 
mids Were digested With Stu I, Which cuts the vectors once 
Within the HIS4 sequences to direct the integration event in 
the his4 locus of the host GS115 strain. Transformants Were 
selected on MD media Which lacks histidine. A single copy 
of the plasmids of transformed strains of transformed strains 
Was determined by Southern blot assay. At least three 
independent single-copy transformants Were chosen, 
induced in MM media, and [3-Gal activity Was monitored in 
the strains. One representative strain Was used for further 
studies. At least three independent induction experiments in 
MM and MME media Were done to estimate the [3-gal 
activity. 
DNA Probes for Gel Shift Assays. 
Second round SDM (site directed mutagenesis) Was done 
to purify plasmids pMMI132, pMMI285, pMMI424, 
pMMI551 to release fragments B (SEQ ID NO: 17), C (SEQ 
ID NO: 18), D (SEQ ID NO: 19) and E (SEQ ID NO: 20), 
respectively. The Eco RI fragment of pMMI132 and the Eco 
RI/Sma I fragment of pMMI669 Were used as fragments A 
(SEQ ID NO: 16) and F (SEQ ID NO: 21), respectively. 
Each fragment Was puri?ed from agarose gel and end 
labeled With DNA polymerase using infrared labeled DATP 
(Li-Cor Inc, Lincoln, Nebr.) 
Preparation of Yeast Cell Extracts. 
Yeasts Were groWn in 25 ml of MM or MME media at 30° 
C. to 1.5 OD (600 nm). The cells Were centrifuged at 
2,000><g at room temperature, Washed tWice With 1M sor 
bitol and suspended in 500 ml of Buffer C [20 mM HEPES 
pH 8.0, 0.2 mM EDTA, 0.5 mM dithiotretiol (DTT), 0.5 mM 
PMSF (phenylmethylsulfonyl ?uoride), 0.42 M NaCl, 1.5 
mM MgCl2 and 25% glycerol]. The cells Were broken With 
glass beads (0.45—0.5 mmin diameter) in a bead beater 
(Biospec Products) (7><30 sec). After centrifugation at 
19,000><g for 15 minutes at 4° C., the supernatant Was used 
for gel retardation assays. Total protein from cell extracts 
Was estimated by the BCA assay (Pierce) using BSA as a 
standard protein. 
Gel retardation assay. The binding reaction mixtures 
contained 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM 
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DTT, 2 mg of poly (dI-dC)'poly (dI-dC) (deoxyinosine 
deoxycytosine), 0.05% Nonidet-40, 10% glycerol and end 
labeled DNA in a volume of 20 ml. The binding reaction 
mixtures included 6 mg of protein extract. After 20 min of 
incubation at room temperature, mixtures Were loaded on to 
a 6% non-denaturing pre-casted polyacrylamide gel (Novex, 
Carlsbad, Calif.). Electrophoresis Was carried out at 10 v/cm 
of gel for 90 min in TBE (45 mM Tris/borate, 1 mM EDTA). 
The gels Were dried and scanned With a prototype Y-axis 
scanner using Base ImagIR v. 4.0 softWare (Li-Cor, Lincoln, 
Nebr.). 
Results 
Regulation of Deletion Derivatives of AOX1 Promoter. 
The plasmids carrying sequential deletions (pAL series) 
and dropout mutations (pDAL series) Were integrated into 
the his4 locus of chromosome of R pastoris GS115 strain 
and single-copy transformants Were screened by Southern 
blot analysis (results not shoWn). At least three single-copy 
transformants Were screened by [3-gal expression in MM 
medium, and one representative strain Was used for further 
induction experiments. Each transformant Was cultured in 
MGY (minimal glycerol media) media overnight. The cul 
ture Was used to inoculate MM and MME media, With cells 
Were groWn to an optical density of 1.5—2.0 (600 nm) prior 
to harvesting. The activity of the AOX1-lacZ fusion Was 
measured and reported as percent of activity of methanol 
groWn cells containing pAL2. 
Each of the deletion derivatives of the AOX1 promoter 
decreased [3-Gal activity in MM media compared to the 
native promoter (FIG. 2). Loss of fragment D (SEQ ID NO: 
19)(—518/—390) (pAL551) resulted in about a tWo-fold 
increase of [3-gal activity, relative to pAL424, While loss of 
fragment E (SEQ ID NO: 20) (—390/—239) had the most 
severe effect on the expression. 
The sequential deletions do not alWays re?ect the relative 
promoter activity since the cumulative effect of cis-acting 
sequences is neglected. Therefore, a series of AOX1 pro 
moter derivatives Were constructed With internal deletions 
(pALDs) to determine the exclusive effect of each fragment. 
Only loss of sequences B (SEQ ID NO: 17) and E (SEQ ID 
NO: 20) had a signi?cant effect on lacZ expression, sug 
gesting that positive elements are located Within these 
deletion intervals. The most signi?cant effect on [3-gal 
activity Was observed by deletion of the fragment E (SEQ ID 
NO: 20)(—390/—239) Where the AOX1 promoter lost 84% of 
activity. 
Although the deletion derivatives of the AOX1 promoter 
had a signi?cant effect on the promoter activity of methanol 
groWn cells, the deletion and dropout plasmids did not 
impair ethanol induced repression of the AOX1 promoter 
(FIG. 2). 
Gel Retardation Assays. 
The GS115 (pAL2) strain Was used to obtain total protein 
extracts groWing in repressed (MME) or induced (MM) 
conditions. The fragments A, B, C, D, E and F (SEQ ID NO: 
16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ 
ID NO: 20, and SEQ ID NO: 21, respectively) Were tested 
in gel-shift assays. The fragment A (SEQ ID NO: 16) 
resulted in formation of speci?c DNA-protein complex 
When the cells Were groWn under induced condition 
(methanol) (FIG. 3, lane 2). HoWever, the ethanol groWn 
cell-protein extracts did not reveal any DNA-protein com 
plexes (FIG. 3, lane 6). Speci?city Was tested by adding 
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unlabeled competitor and unlabeled nonspeci?c DNA 
(Lanes 3 and 5). TWo mg poly dI.dC poly dI.dC and 500-bp 
Listeria moncytogenes gene product Were used as nonspe 
ci?c DNAs. The addition of competitor (unlabeled A 
fragment) resulted in loss of the signal (lane 3). 
Furthermore, addition of the unlabeled fragment C (SEQ ID 
NO: 18)(lane 4) did not compete With fragment A (SEQ ID 
NO: 16) implying that DNA binding for the fragment C 
(SEQ ID NO: 18) is speci?c and the protein binding to 
fragmentA(SEQ ID NO: 16) does not form a complex With 
fragment C (SEQ ID NO: 18). 
The gel shift assay using fragment C (SEQ ID NO: 18) 
and total protein extracted from yeast cells under induced 
and un-induced conditions revealed the formation of speci?c 
DNA-protein complexes. In this case the fragment A (SEQ 
ID NO: 16) and nonspeci?c DNA (L. monocytogenes DNA) 
did not compete for the protein (FIG. 4, lanes 4,8 and lanes 
5, 9, respectively). 
Extract from ethanol/methanol groWn cells forms a com 
plex With fragment C (SEQ ID NO: 18), but the intensity of 
the signal Was Weaker than that observed With methanol 
groWn cells using the same amount of total cell extract (6 mg 
total protein). 
The gel shift assays using the fragments B (SEQ ID NO: 
17), D (SEQ ID NO: 19), E (SEQ ID NO: 20), and F (SEQ 
ID NO: 21) did not reveal any DNA-protein complexes, 
although different gel-shift experiment conditions Were 
tested (results not shoWn). The gel shift results of the 
fragment F (SEQ ID NO: 21) is shoWn in FIG. 5. 
Additionally, FIG. 6 depicts consensus sequences of metha 
nol regulated promoters of methylotrophic yeast. 
In light of the detailed description of the invention and the 
examples presented above, it can be appreciated that the 
several aspects of the invention are achieved. 
It is to be understood that the present invention has been 
described in detail by Way of illustration and example in 
order to acquaint others skilled in the art With the invention, 
its principles, and its practical application. Particular for 
mulations and processes of the present invention are not 
limited to the descriptions of the speci?c embodiments 
presented, but rather the descriptions and examples should 
be vieWed in terms of the claims that folloW and their 
equivalents. While some of the examples and descriptions 
above include some conclusions about the Way the invention 
may function, the inventor does not intend to be bound by 
those conclusions and functions, but puts them forth only as 
possible explanations. 
It is to be further understood that the speci?c embodi 
ments of the present invention as set forth are not intended 
as being exhaustive or limiting of the invention, and that 
many alternatives, modi?cations, and variations Will be 
apparent to those of ordinary skill in the art in light of the 
foregoing examples and detailed description. Accordingly, 
this invention is intended to embrace all such alternatives, 
modi?cations, and variations that fall Within the spirit and 
scope of the folloWing claims. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 29 
TYPE: 
<400> 
aattcccgct 
actcatgttg 
ttcgagatct 
acaggtccat 
ccgttgcaaa 
tatgggcttg 
tttattagcc 
aacaagctcc 
aaatagtttc 
aatatgacaa 
cggccagttg 
tgattgacga 
tgaacccggt 
tatgcattgt 
taacgttcat 
agaaggaagc 
aattgcgact 
gaagatcaaa 
<2l0> 
<2ll> 
TYPE: 
<400> 
ggatctcaaa 
actctctatc 
accaactgga 
cacgcaaacg 
tttcagacca 
cttgattctt 
tagcgccttt 
attgtgatca 
ctaatagagg 
caatactctc 
ccaattgaag 
agatcaaata 
SEQ ID NO 1 
LENGTH: 1052 
DNA 
SEQUENCE: l 
ttgatgcctg 
gtattgtgaa 
aacatccaaa 
tctcacacat 
cgcaggactc 
atggagctcg 
tgtctatcct 
gcattacacc 
atgttcccaa 
aagcgtgatc 
gtcaaaaaga 
atgctcaaaa 
ggcacctgtg 
cctccacatt 
gatcaaaatt 
tgccctgtct 
ggttccaatt 
aaacaactaa 
SEQ ID NO 2 
LENGTH: 1757 
DNA 
SEQUENCE: 2 
aacctaagta 
taggctctag 
tgtcctaacg 
tccccagttc 
tatgaccggt 
ttatgattca 
tctgaaaaac 
agaagcagag 
ttcgatactt 
tcgttcttcg 
gctacgagat 
tccatttatc 
ORGANISM: Pichia pastoris 
aaatcccagc 
atagacgcag 
gacgaaaggt 
aagtgccaaa 
atcctcttct 
ctcattccaa 
ggcccccctg 
cgaacatcac 
atggcccaaa 
tcatccaaga 
aacttccaaa 
ataatctcat 
ccgaaacgca 
gtatgcttcc 
taactgttct 
taaacctttt 
gacaagcttt 
ttattcgaaa 
ORGANISM: Pichia pastoris 
cttcatttga 
atttgataga 
aaatggttct 
gatcctgggc 
ccatcttcta 
aatcactttt 
atttactaaa 
acaatcacca 
attttgataa 
tctcgtcagc 
accagactat 
cagaatcaat 
gcctacaatg 
atcgggaaca 
tgaatgaaac 
cgcaacagga 
ctaacaccat 
ttccttctat 
gcgaggtcat 
tccagatgag 
actgacagtt 
tgaactaagt 
agtcgccata 
taatgcttag 
aatggggaaa 
aagattctgg 
aacccctact 
tttttatcat 
tgattttaac 
atataactct 
ttctatagcc 
gtggtctagt 
agaatcatta 
Cggggggatt 
acgttattta 
aatcatacat 
ctaaggttgc 
tacgacatat 
taaaaatata 
cactagtaga 
taccttcctt 
atgacatttg 
ctgaaaaata 
ctttttgcca 
ggggatacac 
tttgcatgaa 
taggctacta 
gtttgtttat 
ggctttctga 
taaacgctgt 
ttggttcgtt 
ccgtttgtct 
cgcagtctct 
caacccgctt 
tgggaatact 
tggacaggca 
cattattagc 
gacttttaac 
gcacctaaaa 
tttggtttgt 
tggttatggc 
ttttttgacc 
atctatgctt 
ttacttactg 
cggcactcta 
acatttgagc 
tgtcttacct 
acacttcgag 
actttgacat 
tagcttgtcg 
gatttggttg 
acagttatta 
tccgacatcc 
tagcagcaga 
aacagccagt 
acaccatgac 
ttccgaatgc 
gtgtggggtc 
cttggaacct 
gaaatcctaa 
tgtttggtat 
ctatcgcttc 
tttggatgat 
gctgatagcc 
atatataaac 
ttactttcat 
gacaacttga 
tttacaccta 
tatagtgttc 
atatgcttaa 
gaattctttt 
tgacctctat 
gttatttact 
aacacgacag 
cagtaggctc 
ctgaatgtgt 
taagatacgc 
ctgctaaagc 
aaggcatgaa 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1052 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
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aaCaaaaaCa aCtaattatt CgaaaCaatg gCtattCCCg aagaatttga tattatCgtC 
tgtggtggtg gatCC 
SEQ ID NO 4 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Yeast 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (41) . . (4 ) 
OTHER INFORMATION: n=unknown 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (5) . . (5 ) 
OTHER INFORMATION: n=unknown 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (6) . . (6) 
OTHER INFORMATION: n=unknown 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (16) . . (16) 
OTHER INFORMATION: n=unknown 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (17 ) . . ( 17) 
OTHER INFORMATION: n=unknown 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (15 ) . . ( 15) 
OTHER INFORMATION: n=unknown 
SEQUENCE: 4 
ttgnnngctt CCaannntgg t 
SEQ ID NO 5 
LENGTH: 10 
TYPE: DNA 
ORGANISM: Yeast 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (3) . . (3) 
OTHER INFORMATION: n=unknown 
SEQUENCE: 5 
CCnCtttttg 
SEQ ID NO 6 
LENGTH: 16 
TYPE: DNA 
ORGANISM: Yeast 
SEQUENCE: 6 
gCtCattCCa attCCt 
SEQ ID NO 7 
LENGTH: 16 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: 7 
CtgtCttgga aCCtaa 
SEQ ID NO 8 
LENGTH: 16 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: 8 
1080 
1095 
21 
10 
16 
16 
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-continued 
26 
gaaacttcca aaagtc 
SEQ ID NO 9 
LENGTH: 16 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: 9 
tatgcttcca agattc 
SEQ ID NO 10 
LENGTH: 16 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: l0 
actggttcca attgac 
SEQ ID NO 11 
LENGTH: 15 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: ll 
cctgtctatc ctggc 
SEQ ID NO 12 
LENGTH: 15 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: l2 
tctctctatc gcttc 
SEQ ID NO 13 
LENGTH: 15 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: l3 
ctgctgatag cctaa 
SEQ ID NO 14 
LENGTH: 15 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: l4 
gagttcgagg tcgtg 
SEQ ID NO 15 
LENGTH: 15 
TYPE: DNA 
ORGANISM: methylotrophic yeast 
SEQUENCE: l5 
gagtgtgggg tcaaa 
SEQ ID NO 16 
LENGTH: 256 
TYPE: DNA 
ORGANISM: Pichia pastoris 




